Spitze in der Medizin. Menschlich in der Begegnung.
Regensburg University Hospital leads the field in research, teaching and patient care. We employ 5000 dedicated colleagues, who provide first rate medical care for the whole of Eastern Bavaria. We offer cutting-edge medicine, and our top professionals have access to the latest and best equipment. We are committed to the highest level of medical and nursing care for our patients, and to a teamwork that respects and values our personnel.
For the project A02 "Efficacy and safety of HLA-DPB1-specific chimeric antigen receptors (CAR) as mediators of GvL effect" the CRC/TRR 221 offers a
PhD position (m/f/d)
The full-time position is located in Regensburg and currently limited to 4 years, starting from January 1st 2026 or later. Remuneration is according to TV-L (E13; 65%).
Scientists in Regensburg, Erlangen and Würzburg work together in the Collaborative Research Center/Transregio (CRC/TRR) 221 that focuses on unsolved challenges in the treatment of patients with leukemia and lymphoma. The researchers aim at the improvement of allogeneic hematopoietic stem cell transplantation by modulation of graft-versus-host and graft-versus-leukemia immune responses.
PhD position in the SFB Transregio 221
The research project is part of the SFB-TRR221 in the third funding period from 1st Jan 2026. In our project, we employ CAR T cells to target HLA-restricted antigens, enabling selective targeting of AML blasts.
The research project is part of the SFB-TRR221 in the third funding period from 1st Jan 2026. In our project, we employ CAR T cells to target HLA-restricted antigens, enabling selective targeting of AML blasts.
Your Tasks
The PhD project is focused on the engineering, optimization, and in vivoevaluation of advanced adapter CAR technologies for the treatment of acute myeloid leukemia in the allogeneic stem cell transplantation setting. Various CAR constructs and adapter-molecule formats will be generated and characterizedin vitro for cytotoxicity, cytokine production, effector cell proliferation, CAR T cell immunophenotype, longevity, and fitness. Most promising CAR and adapter molecule candidates will be selected for in vivoevaluation. The program will elucidate the use of disparate HLA-types to selectively enhance the targeting of leukemic blasts posttransplant. The work is conducted at the Leibniz Institute for Immunotherapy (LIT) as part of a thriving, interdisciplinary scientific ecosystem, in close collaboration with other research groups at the LIT and with clinical partners at the UKR. We aim to deliver a translational CAR technology for clinical use.
The PhD project is focused on the engineering, optimization, and in vivoevaluation of advanced adapter CAR technologies for the treatment of acute myeloid leukemia in the allogeneic stem cell transplantation setting. Various CAR constructs and adapter-molecule formats will be generated and characterizedin vitro for cytotoxicity, cytokine production, effector cell proliferation, CAR T cell immunophenotype, longevity, and fitness. Most promising CAR and adapter molecule candidates will be selected for in vivoevaluation. The program will elucidate the use of disparate HLA-types to selectively enhance the targeting of leukemic blasts posttransplant. The work is conducted at the Leibniz Institute for Immunotherapy (LIT) as part of a thriving, interdisciplinary scientific ecosystem, in close collaboration with other research groups at the LIT and with clinical partners at the UKR. We aim to deliver a translational CAR technology for clinical use.
Your profile
We are seeking a highly motivated and curious doctoral candidate (M/F/D) with a strong interest in T cell immunology, protein and CAR engineering, molecular biology, and in vivo work using murine xenograft models. Applicants should hold a Master’s degree in biology, biotechnology, biomedical sciences, pharmaceutical sciences, or a related field. Experience with human T cells and cancer cells, molecular biology, and/or animal models (FELASA B certificate) are advantageous but not mandatory. We are looking for an independent, analytical, and creative researcher with excellent communication skills in English, a collaborative mindset, and enthusiasm for interdisciplinary and translational research in an international environment.
We offer
This project will be conducted in the Clinical Cooperation Group, Pediatric Gene and Cell Therapy (Patrick Schlegel) at the LIT in collaboration with the LIT Lab, T-cell Therapy (Simone Thomas), and Wolfgang Herr (spokesperson of the CRC/TRR221). We offer a stimulating, supportive, and international environment where you can develop your scientific skills and professional potential within a diverse, collaborative research community at the LIT and the CRC Transregio 221.
This project will be conducted in the Clinical Cooperation Group, Pediatric Gene and Cell Therapy (Patrick Schlegel) at the LIT in collaboration with the LIT Lab, T-cell Therapy (Simone Thomas), and Wolfgang Herr (spokesperson of the CRC/TRR221). We offer a stimulating, supportive, and international environment where you can develop your scientific skills and professional potential within a diverse, collaborative research community at the LIT and the CRC Transregio 221.
The appointment will be on a temporary full-time basis for a maximum duration of 48 months (PhD position) from January 2026 or later.
Disabled persons will be given preferential consideration if they are equally qualified. Please indicate any disability in your application.
Please note that expenses that may arise in the context of an eventual job interview cannot be reimbursed.
Please note that expenses that may arise in the context of an eventual job interview cannot be reimbursed.
How to apply
Interested candidates should submit their application via the online portal, including the following documents in English:
- Motivation letter describing research interests, career goals, relevant skills and experience, and explaining how the candidate’s profile aligns with the advertised DC position.
- Complete Curriculum Vitae (CV) with details of previous research and training experience, and contact information for references.
We look forward to receiving your detailed application documents via our online portal by 31.01.2026.
University Hospital Regensburg
Department of Pediatric Hematology, Oncology and Stem Cell Transplantation
Prof. Dr. Corbacioglu, Director
93042 Regensburg
